Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 2
2005 2
2006 2
2007 4
2008 2
2009 2
2010 3
2011 5
2012 4
2013 3
2014 4
2015 2
2016 3
2017 2
2018 2
2019 3
2020 8
2021 11
2022 11
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Immune Checkpoint Inhibitors in Cancer Therapy.
Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K, Kulasinghe A. Shiravand Y, et al. Among authors: o byrne k. Curr Oncol. 2022 Apr 24;29(5):3044-3060. doi: 10.3390/curroncol29050247. Curr Oncol. 2022. PMID: 35621637 Free PMC article. Review.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Park K, et al. Among authors: o byrne k. Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12. Lancet Oncol. 2016. PMID: 27083334 Clinical Trial.
Immunotherapeutic targets in non-small cell lung cancer.
Sadeghirad H, Bahrami T, Layeghi SM, Yousefi H, Rezaei M, Hosseini-Fard SR, Radfar P, Warkiani ME, O'Byrne K, Kulasinghe A. Sadeghirad H, et al. Among authors: o byrne k. Immunology. 2023 Feb;168(2):256-272. doi: 10.1111/imm.13562. Epub 2022 Aug 25. Immunology. 2023. PMID: 35933597 Free article. Review.
Understanding the tumor microenvironment for effective immunotherapy.
Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O'Byrne K, Rezaei N, Kulasinghe A. Sadeghi Rad H, et al. Among authors: o byrne k. Med Res Rev. 2021 May;41(3):1474-1498. doi: 10.1002/med.21765. Epub 2020 Dec 4. Med Res Rev. 2021. PMID: 33277742 Free PMC article. Review.
The Role of Circulating Biomarkers in Lung Cancer.
Herath S, Sadeghi Rad H, Radfar P, Ladwa R, Warkiani M, O'Byrne K, Kulasinghe A. Herath S, et al. Among authors: o byrne k. Front Oncol. 2022 Jan 21;11:801269. doi: 10.3389/fonc.2021.801269. eCollection 2021. Front Oncol. 2022. PMID: 35127511 Free PMC article. Review.
In situ characterization of the tumor microenvironment.
Sadeghirad H, Yaghoubi Naei V, O'Byrne K, Warkiani ME, Kulasinghe A. Sadeghirad H, et al. Among authors: o byrne k. Curr Opin Biotechnol. 2024 Apr;86:103083. doi: 10.1016/j.copbio.2024.103083. Epub 2024 Feb 20. Curr Opin Biotechnol. 2024. PMID: 38382325 Free article. Review.
Spatial profiling technologies and applications for brain cancers.
Kalita-de Croft P, Sadeghi Rad H, Gasper H, O'Byrne K, Lakhani SR, Kulasinghe A. Kalita-de Croft P, et al. Among authors: o byrne k. Expert Rev Mol Diagn. 2021 Mar;21(3):323-332. doi: 10.1080/14737159.2021.1900735. Epub 2021 Mar 19. Expert Rev Mol Diagn. 2021. PMID: 33685321 Review.
Understanding the tumor microenvironment in head and neck squamous cell carcinoma.
Rad HS, Shiravand Y, Radfar P, Ladwa R, Perry C, Han X, Warkiani ME, Adams MN, Hughes BG, O'Byrne K, Kulasinghe A. Rad HS, et al. Among authors: o byrne k. Clin Transl Immunology. 2022 Jun 6;11(6):e1397. doi: 10.1002/cti2.1397. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35686027 Free PMC article. Review.
79 results